Many hormones circulate bound to serum proteins that modulate ligand bioactivity and bioavailability. To understand the biology of leptin action, we investigated the presence of leptin binding proteins in serum.
L eptin, the product of the ob/ob gene (1) is an adipose tissue-derived secreted protein that has been implicated in the regulation of food intake and whole-body energy balance. Administration of exogenous leptin to ob/ob mice, which lack the protein, results in reduced food intake, increased energy expenditure, increased physical activity, and normalization of hyperglycemia and hyperinsulinemia (2) (3) (4) (5) . Leptin effects appear to be exerted, at least in part, at the level of the hypothalamus, since effects are seen in ob/ob mice at far lower doses after intracerebroventricular (ICV) than after peripheral administration (4, 6) . One probable target is hypothalamic neuropeptide Y expression (6) . The expression of leptin and neuropeptide Y appear to be reciprocally regulated (6) (7) (8) . Circulating leptin concentrations are positively correlated with body lipid and are elevated in many models of rodent and human obesity (9) (10) (11) (12) . Thus, a hallmark of obesity is not the absence of leptin, but leptin resistance.
Leptin resistance could result from downregulation of the leptin receptor, defective binding to or signaling from the receptor, altered pathways downstream of leptin, and/or alterations in the bioavailability or bioactivity of circulating leptin. The gene for the leptin receptor was recently cloned and shows sequence homology to the cytokine receptor family (13) (14) (15) . Cytokines circulate bound to a number of binding proteins, which include a 2 macroglobulins, extracellular matrix proteins, monospecific binding proteins, and secreted extracellular domains of cytokine receptors (16, 17) . The leptin receptor is predicted to exist in at least six forms arising from alternative mRNA splicing (14, 15) . One form has a sequence suggesting a soluble receptor that could act as a binding protein for circulating leptin. Potential functions of binding proteins include altering the clearance rate of hormones or cytokines, increasing or decreasing the biological activity of the ligand, and/or providing hormone responsiveness to unresponsive cells. Little is known about the properties of circulating leptin in rodents and humans. Using multiple biochemical approaches, we provide evidence that 2) the majority of leptin circulates bound to protein(s) in serum from mice and humans, 2) there are multiple leptin-binding species, and 3) the phenomenon is influenced, at least in part, by obesity.
RESEARCH DESIGN AND METHODS
Human subjects and animals. Blood samples were collected with informed consent from seven Caucasian women ranging in age from 32 to 66 years. Six subjects had no known medical problems, while a morbidly obese subject had mild NIDDM. Subjects fasted overnight before blood sampling unless otherwise indicated. Mouse strains studied included FVB, ob/ob, db/db, and brown-fat-deficient (UCP-DTA, uncoupling protein promoter driving diphtheria toxin alpha [18] ). Blood samples were collected by cardiac puncture at time of killing or from the tail vein of live male and female mice. Obesity was induced in male FVB mice (4 weeks old) by injection of goldthioglucose (GTG; 0.5 mg/g body wt; #50833 Fluka, Ronkonkoma, NY) after an overnight fast. GTG-injected mice were killed at 8 weeks of age, and blood was collected. All mice were housed at 21°C with a 12-h light/dark cycle and were fed standard Rodent Chow (Purina #5008) or a high-fat diet (55% of calories from fat, 24% carbohydrate, 21% protein, as previously described [19] ) ad libitum. The high-fat diet was initiated at weaning (3 weeks) and continued for 10 weeks. Mice were killed by CO 2 inhalation followed by cervical dislocation. I-leptin to proteins in serum of mice and humans (C). A: plasma or serum samples pooled from two to six lean or obese FVB mice were electrophoresed in the presence (+0ME) or absence (-(iME) of 5% pME and in the presence of SDS (4%) and blotted for leptin as described in METHODS. B: serum from two to four UCP-DTA brown-fat-ablated transgenic mice compared with that from lean FVB littermates. C: sera from two to four normal FVB or ob/ob mice and from nonobese women were electrophoresed in the presence of 4% SDS without PME in 16% (mouse) or 8% (human) Tris/glycine gels and blotted with 125 I-labeled recombinant murine or human leptin (± 1.0 ug recombinant murine leptin) as described in METHODS. Data are representative of two experiments for each condition.
Immunoblotting and ligand blotting. Serum samples (5 ul) from mice or humans were mixed with loading buffer (450 mmol/1 Tris-HCl, 12% glycerol, 4% SDS, 0.0025% Coomassie blue G, 0.0025% Phenol red) in the absence or presence of p-rnercaptoethanol (pME) (5%). Samples were electrophoresed in 16% tricine gels and transferred to PVDF. Filters were blotted for leptin as previously described (11) . For ligand blotting, serum samples were mixed with loading buffer and were electrophoresed under nonreducing conditions in 16 or 8% Tris/glycine gels and transferred to polyvinylidene fluoride (PVDF). Membranes were blocked with 5% bovine serum albumin (BSA; Sigma, radioimmunoassay [RIA] grade) for 2 h at room temperature, after which blots were incubated with 125 I-labeled mouse or human leptin (Linco Research, St. Louis, MO) in Tris-buffered saline (TBS) (1% BSA) overnight at 4°C. Blots were washed twice in TBS (0.1% Tween-20) and exposed to film. Additionally, human serum was incubated with 125 I-leptin for 30 min at 37°C and was then electrophoresed under denaturing (4% SDS) but nonreducing conditions in 8% Tris/glycine gels. Gels were dried and subjected to autoradiography. Sucrose gradient centrifugation. Leptin sedimentation profiles were determined by rate-zonal centrifugation in continuous sucrose gradients (5-20% sucrose in phosphate-buffered saline [pH 7.4]). Sera or standards (lysozyme, SI.9; bovine serum albumin, S4.3; fibrinogen, S7.9; catalase, S11.3) were loaded in a final volume of 100 ul. For radioisotope binding studies, serum was incubated in the presence of tracer quantities of 126 Mabeled murine or human leptin (-1,600 cpm/ul) for 30 min at 37°C. To test the specificity of ligand binding, one sample per treatment was simultaneously incubated with 1.0 ug recombinant murine leptin (Eli Lilly, Indianapolis, IN). Gradients were centrifuged at 200,000^ for 7 h at 4°C in a TLS-55 swinging-bucket rotor. Fractions were analyzed for 126 I-leptin using a gamma counter or analyzed for endogenous leptin by RIA (Linco Research). The limit of detection was 0.2 ng/ml, and the intra-assay coefficient of variation was 4.39% for lowlevel controls (2.9 ng/ml) and 5.66% for high-level controls (14.1 ng/ml). Interassay variation was 6.9 and 9% for low and high controls, respectively.
RESULTS
Ligand blotting and immunoblotting. Electrophoresis of mouse serum or plasma under denaturing and reducing (+(3ME) conditions results in the expected immunoreactive band of 16 kDa, which represents free leptin (Fig. LA) . However, under nonreducing conditions (-pME), the 16-kDa band is not detectable and three higher molecular mass immunoreactive bands are visible (Fig. LA) . A similar phenomenon is observed in serum from obese UCP-DTA mice compared with that from non- transgenic lean FVB littermates (Fig. IB) . These data suggest that a large fraction of leptin in serum and plasma exists in "higher molecular mass" forms that may involve sulfhydryl/disulfide bonds. It is possible that these higher molecular mass species could be multimers of leptin/binding protein complexes.
125
I-leptin competitively bound to immobilized proteins in mouse and human serum (Fig. 1C) . Radioligand blotting of normal mouse serum revealed specific competitive binding of 125 I-leptin to proteins of apparent molecular masses -240, -176, and -85 kDa (Fig. 1C) . Binding to the 85-kDa band was absent or very low in serum from female ob/ob mice (Fig. 1C) and was somewhat reduced in GTG obese treated mice (not shown). In human serum, leptin bound to proteins with apparent molecular masses of -240 and -176 kDa (nonreducing conditions), and binding was completely inhibited by competition with 1 ug recombinant leptin ( Fig. 1(7) . Similarly, when human serum was preincubated with 125 I leptin and then subjected to nonreducing gel electrophoresis, radioactive bands were observed at -240 and -176 kDa (not shown). The 85-kDa band observed in mouse samples was either absent or below the level of detection in human samples. I-leptin, presumably due to complex formation with other molecules in serum. Using iodinated hormones to assess biological functions always carries the risk of altering the bioactivity or the specificity of binding of the hormone by iodination. In our studies, iodination of leptin does not appear to disrupt its binding to serum protein(s) or to create nonspecific binding, since the shift of the peak to the approximate S4.3 region is completely inhibited with 1 ug cold murine recombinant leptin ( Fig. 2A) . The fact that 125 I-leptin binding demonstrated by an independent technique, ligand binding (Fig.  1C) , is also competed with cold leptin provides further evidence that 125 I leptin binding is specific. I-leptin in the presence ( • ) or absence ( • ) of female human serum or in the presence of human serum and 1.0 ug recombinant murine leptin (X) was subjected to continuous sucrose gradient centrifugation as described in METH-ODS. The data show results for serum from a Caucasian woman in the fed state, age 32 years, BMI 27, waist-to-hip ratio 0.72, serum leptin 9.3 ng/ml. This sample was analyzed in duplicate and nearly identical results were obtained. These data are representative of five different women.
A similar binding phenomenon is observed when serum from female mice fasted for 24 h is analyzed (Fig.  2E) . However, with serum from high-fat-fed obese mice (Fig 2(7) , db/db mice, which lack functional leptin receptors (Fig 2D) , or ob/ob mice, which lack full-length leptin (Fig 2E) , the shift in leptin sedimentation is attenuated. Leptin sedimentation profiles for male mice also illustrate a binding phenomenon that is competitively inhibited with 1 ug cold leptin and is reduced with genetic (UCP-DTA) and high-fat-induced obesity (not shown). Figure 2F shows that the shift is obliterated in males with GTG-induced obesity, the model with the highest serum leptin levels.
The leptin binding shift is also observed with human serum (Fig. 3) .
I-leptin specifically interacts with protein(s) to cause a shift toward the approximate S4.3 peak. The data shown are for serum from a woman with a BMI of 27. These data are representative of data for five different women. In serum from one morbidly obese woman (BMI 38), the shift was reduced. Fasting in women does not alter the ability of 125 I-leptin to bind to serum protein(s) (not shown).
To determine the sedimentation profile of endogenous leptin in mice and humans, serum was analyzed by sucrose gradient centrifugation and RIA (Fig. 4) . In women (Fig.  4A) , immunoreactive leptin in serum is found both free (S-1.9) and bound (S>1.9). The amount of free leptin increases with BMI and appears most affected by the total leptin level (as measured by RIA). This is consistent with the notion that the binding proteins are saturated in obese states characterized by significantly elevated circulating leptin. In one additional lean subject with low leptin levels, leptin measurements were at the limit of detection of the assay and therefore are not shown.
In lean mice with low circulating leptin (2.5 and 3.5 ng/ml; Fig. 45 ), the immunoreactive leptin is predominantly found in the bound state, although a portion is free (S-1.9). However, with brown-fat-deficient (UCP-DTA) or high-fat-induced obesity (Fig. 4B) , serum leptin levels are elevated (UCP-DTA, leptin = 13.5 ng/ml) and a major portion is found in the free state, again suggesting saturation of the endogenous binding protein(s). This is most clearly seen in the GTG-treated mouse, which is massively obese, has very high serum leptin concentrations (28.5 ng/ml; Fig. 4(7) , and the highest peak of free leptin (S-1.9). The profile is shown in relation to obese UCP-DTA mice (note change in scale).
DISCUSSION
In the present study, we use multiple experimental approaches to show that a major portion of leptin does not circulate as a 16-kDa monomeric species in normal mice and humans. Ligand binding illustrates that radioactive leptin competitively binds to two (human) or three (mouse) serum proteins (Fig. 1) , and immunoblotting indicates that the leptin binding is reversed by reducing agents. Thus, either leptin binds to the binding proteins via sulfhydryl/disulfide bonds or such interactions within the binding proteins critically affect their ability to bind leptin.
Sucrose gradient centrifugation, which separates molecular complexes on the basis of size and shape under native conditions, was used to analyze 125 I-leptin interactions with serum macromolecules(s). These data provide independent evidence for the leptin binding phenomenon (Figs. 2 and 3) . Serum incubation results in a shift of free monomeric leptin from a sedimentation coefficient of -1.9 to a larger complex (S-4.3), and this is blocked by excess cold leptin. We would predict from ligand binding data that the binding complex would be larger than indicated by S value. However, the approximate S4.3 is compatible with leptin binding to the -85-kDa protein if the complex has significant asymmetry, since asymmetrical particles sediment more slowly than spherical particles of the same mass and density. The conditions used for sucrose gradient analyses were optimized to resolve the S-4.3 peak because of the large effect seen. It is possible that leptin binding to additional serum proteins could be resolved under different conditions (i.e., larger complexes may be lost in the pellet, fraction 12). The ability of exogenous leptin to form this particular binding complex is attenuated in several models of obesity but not of fasting. This is consistent with the notion that available leptin binding sites are saturated with elevated circulating leptin levels present in obesity. The fact that the greatest diminution of binding was observed in the model with the highest circulating leptin, the GTG-treated mouse, supports this hypothesis.
The hypothesis of saturation of serum leptin-binding sites in obesity is further supported by data on endogenous leptin sedimentation profiles (Fig. 4) . In nonobese mice and humans, a significant portion of endogenous leptin is bound (S>1.9). With increasing severity of obe- sity and increasing circulating leptin levels, leptin "spills over" into the free (S-1.9) pool. The fact that free leptin is detected in serum by RIA and not by nonreducing immunoblotting (Fig. 1 ) most likely reflects the greater sensitivity of the RIA. The physiological consequences of increased free leptin are unknown, but free leptin may have more rapid turnover because of proteolytic cleavage or increased clearance. This hypothesis is supported by the observation that the half-life (t l/2 ) of recombinant leptin injected into ob/ob mice is much shorter than that in normal mice (R. Frederich and J.S.F., unpublished observations). One must be cautious in interpreting these data, since it is currently unknown whether binding proteins interfere in the radioimmunoassay. Such interference could have a significant impact on the estimation of leptin levels by RIA. One possible role for the binding proteins is to facilitate the transport of leptin across the blood-brain barrier to its hypothalamic (or other) site(s) of action. Precedent for an important role for binding proteins in the transport or uptake of ligands has been demonstrated for other members of this family (16, 17) . Additionally, for some cytokines and hematopoietic growth factors, association with binding proteins potentiates ligand activity because of biochemical modifications (16, 17) . These phenomena provide possible explanations for apparent leptin resistance in the setting of increased free leptin.
Binding of 125 I-leptin to the ~85-kDa protein is severely reduced or absent in serum from ob/ob mice (Fig. 1) , which lack leptin (full-length protein). This most likely reflects downregulation of this binding protein similar to the downregulation of growth hormone-binding protein in states of growth hormone deficiency (20) . Leptin may regulate the expression or degradation of this ~85-kDa binding protein. The fact that the binding phenomenon, as tested by sucrose gradient centrifugation (Fig. 2E) , is not exaggerated in ob/ob serum (because of an absence of competition from endogenous leptin) is consistent with reduced levels of one or more binding proteins. We cannot rule out, however, that a mutant truncated form of leptin binds to and saturates serum binding protein(s). The ~85-kDa protein is the predicted molecular mass of the soluble splice variant of the leptin receptor (15) . We are currently in the process of developing antibodies to the leptin receptor to test whether this protein is the soluble form of the receptor.
In summary, using several biochemical approaches, we provide the first evidence that leptin circulates in multiple-molecular mass protein complexes in serum in humans and mice and that this binding is modulated by obesity. This binding phenomenon may have a major impact on the biological activity of leptin in normal and pathophysiological states. Future studies will focus on the isolation of these binding proteins, which will allow biochemical and kinetic evaluation of leptin/binding protein interactions. Regulation of these binding proteins may play a critical role in the adipose tissue neuroendocrine axis that regulates food intake and energy balance.
